UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. URGN from Buy to Neutral.

Selvaraju points out that the FDA’s Oncologic Drugs Advisory Committee voted 5-4 against the benefit-risk profile of UroGen’s investigational therapy UGN-102 (mitomycin for intravesical solution), intended for patients with recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC).

According to the analyst, the narrow negative vote significantly lowers the likelihood of UGN-102 receiving timely approval.

Also Read: UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates

Selvaraju notes that if UGN-102 does receive FDA approval next month — with the only condition being a post-marketing randomized, controlled trial — this scenario would warrant a reassessment of their current rating on the stock.

Selvaraju notes that UroGen concluded the first quarter of 2025 with approximately $200 million in cash, cash equivalents and marketable securities.

According to the analyst, this financial position should be adequate to sustain operations through late 2026, even if UGN-102 fails to secure regulatory approval.

For 2026, the analyst now forecasts a net loss of $2.14 per share, a notable shift from his earlier projection of 27 cents in earnings for the year.

Get Started

Earn 7.2% — No Matter What the Fed Does

Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Get Started

Selvaraju highlights that UroGen is advancing development on UGN-103 and UGN-104, next-generation mitomycin-based formulations for UGN-102 and JELMYTO, respectively.

These candidates combine the company’s RTGel delivery platform with a novel mitomycin formulation licensed from medac GmbH.

The Phase 3 UTOPIA trial evaluating UGN-103 in patients with low-grade, intermediate-risk non-muscle-invasive bladder cancer is currently enrolling.

Selvaraju anticipates that enrollment will wrap up by mid-2025, with top-line data expected shortly after. If results are positive, a regulatory submission could occur in 2026, potentially leading to FDA approval by 2027.

URGN Price Action: Urogen shares closed at $4.19 on Friday.

Read Next:

• Trump’s Big Tax Bill Clears The House: 30-Year Yields Jump To 5.15% As Bond Market Freaks

Photo: Shutterstock